Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-03-28

Clinical Trial Update: Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of REGN1033 (SAR391786) in patients with sarcopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • REGN1033 (SAR391786) (REGN1033)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Sarcopenia | Phase 2 | Status: COMPLETED